Pharmacologic studies in vulnerable populations: Using the pediatric experience

Area of Science:

• Pharmacology
• Clinical Trials
• Drug Development

Background:

• Historically, a lack of data exists for guiding drug dosing in pediatric and pregnant populations.
• Barriers to clinical trial inclusion for these vulnerable groups have resulted in significant knowledge gaps.
• Despite common therapeutic use, research in pregnant women lags behind pediatric advancements.

Purpose of the Study:

• To review historical challenges in pediatric and pregnant drug research.
• To highlight successful strategies in pediatric clinical pharmacology.
• To propose the pediatric drug development model for improving research in pregnant women.

Main Methods:

• Review of federal legislation impacting pediatric therapeutics.
• Analysis of innovative clinical trial designs.
• Application of quantitative clinical pharmacology methods.
• Examination of collaborative efforts and thought leadership in pediatric research.

Main Results:

• Successful overcoming of barriers has led to improved knowledge of pharmacokinetics, safety, and efficacy in children.
• Significant knowledge gaps persist regarding drug use in pregnant women.
• The pediatric success offers a potential model for pregnant women's drug research.

Conclusions:

• Strategies employed in pediatric drug development can serve as a model for advancing drug research in pregnant women.
• Improved drug knowledge in pregnant populations is crucial due to widespread therapeutic use.
• Overcoming similar barriers is key to ensuring safe and effective medication administration in both populations.